Peripartum mood disturbances pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 30: Line 30:
|[[Glutamate]] is the [[excitatory neurotransmitter]] in the brain
|[[Glutamate]] is the [[excitatory neurotransmitter]] in the brain
|[[Serotonin]] to [[5HT1A]] [[receptors]] is decreased in the following brain regions
|[[Serotonin]] to [[5HT1A]] [[receptors]] is decreased in the following brain regions
|[[Mutations]] in [[DR1]]  
|[[Mutations]] in [[DR1]]
|-
|-
|Level is inversely related with the [[depression]] [[symptoms]] in  the [[postpartum]] period
|Level is inversely related with the [[depression]] [[symptoms]] in  the [[postpartum]] period
|[[postpartum depression]] its level are increased in the [[Medial prefrontal cortex|medial prefrontal]] [[cortex]]  
|[[postpartum depression]] its level are increased in the [[Medial prefrontal cortex|medial prefrontal]] [[cortex]]
|[[mesiotemporal]] and  anterior [[cingulate]] [[cortices]].
|[[mesiotemporal]] and  anterior [[Cingulate cortex|cingulate cortices]].
|Relates to the attention and affection of mother for the baby
|Relates to the attention and affection of mother for the baby
|-
|-

Revision as of 20:40, 2 August 2021

Peripartum mood disturbances Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Peripartum mood disturbances from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Peripartum mood disturbances pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peripartum mood disturbances pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peripartum mood disturbances pathophysiology

CDC on Peripartum mood disturbances pathophysiology

Peripartum mood disturbances pathophysiology in the news

Blogs on Peripartum mood disturbances pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Peripartum mood disturbances pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunita Kumawat, M.B.B.S[2]

Overview

Many pathological mechanisms are involved in postpartum depression which interact with one another.

Pathophysiology

Physiology

The normal physiology of [name of process] can be understood as follows:

Pathogenesis

GABA Glutamate Serotonin Dopamine
GABA which is an inhibitory neurotransmitter in the brain Glutamate is the excitatory neurotransmitter in the brain Serotonin to 5HT1A receptors is decreased in the following brain regions Mutations in DR1
Level is inversely related with the depression symptoms in the postpartum period postpartum depression its level are increased in the medial prefrontal cortex mesiotemporal and anterior cingulate cortices. Relates to the attention and affection of mother for the baby
In postpartum depression decreased in the dorsolateral prefrontal cortex.

It is thought that in postpartum psychosis, immunoneuroendocrine set point is dysregulated with overactivation of the immune system's macrophage and monocyte arm. [2]

Genetics

[Disease name] is transmitted in [mode of genetic transmission] pattern.

OR

Genes involved in the pathogenesis of [disease name] include:

  • [Gene1]
  • [Gene2]
  • [Gene3]

OR

The development of [disease name] is the result of multiple genetic mutations such as:

  • [Mutation 1]
  • [Mutation 2]
  • [Mutation 3]

Associated Conditions

Conditions associated with [disease name] include:

  • [Condition 1]
  • [Condition 2]
  • [Condition 3]

Gross Pathology

On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

References

  1. Payne JL, Maguire J (January 2019). "Pathophysiological mechanisms implicated in postpartum [[depression]]". Front Neuroendocrinol. 52: 165–180. doi:10.1016/j.yfrne.2018.12.001. PMC 6370514. PMID 30552910. URL–wikilink conflict (help)
  2. Davies W (June 2017). "Understanding the pathophysiology of [[postpartum]] [[psychosis]]: Challenges and new approaches". World J Psychiatry. 7 (2): 77–88. doi:10.5498/wjp.v7.i2.77. PMC 5491479. PMID 28713685. URL–wikilink conflict (help)